Phase 3 Epilepsy trials in Thailand

Showing 1 to 17 of 17. Each trial links to its page on Pharma Observatory.

• A Study to Evaluate the Efficacy and Safety of Brivaracetam in Study Participants (>=16 to 80 Years of Age) With Epilepsy NCT03083665·Phase 3·Completed·UCB Biopharma SRL·Started 2017
• Efficacy and Safety of Lacosamide as Adjunctive Therapy in Subjects ≥1 Month to <4 Years With Partial-onset Seizures NCT02477839·Phase 3·Completed·UCB BIOSCIENCES, Inc.·Started 2015
• A Safety, Efficacy, and Tolerability Trial of Pregabalin as Add-On Treatment in Pediatric Subjects <4 Years of Age With Partial Onset Seizures. NCT02072824·Phase 3·Completed·Pfizer's Upjohn has merged with Mylan to form Viatris Inc.·Started 2014
• A Clinical Study to Investigate the Efficacy and Safety of Lacosamide as an Add on Therapy in Children With Epilepsy With Partial-onset Seizures NCT01964560·Phase 3·Completed·UCB BIOSCIENCES, Inc.·Started 2014
• Study to Investigate Lacosamide as Add-on Therapy in Subjects ≥4 Years to <17 Years of Age With Partial Onset Seizures NCT01921205·Phase 3·Completed·UCB Pharma·Started 2013
• A Long-term, Safety, Tolerability, and Efficacy Study of Retigabine Immediate-release (IR) in Asian Adults With Partial Onset Seizures NCT01777139·Phase 3·Completed·GlaxoSmithKline·Started 2013
• Assessment of the Efficacy and Safety of 2 Doses of Retigabine Immediate Release (900 mg/Day and 600 mg/Day) Used as Adjunctive Therapy in Adult Asian Subjects With Drug-resistant Partial-onset Seizures NCT01648101·Phase 3·Terminated·GlaxoSmithKline·Started 2012
• Evaluating Long Term Safety of Lacosamide (LCM) to Carbamazepine Controlled-release (CBZ-CR); Initial Monotherapy in Epilepsy Subjects 16 Years and Older NCT01465997·Phase 3·Completed·UCB BIOSCIENCES GmbH·Started 2012
• A Study With an Open-label Extension Phase to Evaluate the Efficacy and Safety of Perampanel (E2007) Administered as an Adjunctive Therapy in Subjects With Refractory Partial-onset Seizures NCT01618695·Phase 3·Completed·Eisai Co., Ltd.·Started 2012
• A 12-Month Study To Evaluate The Safety And Tolerability Of Pregabalin As Add-On Therapy In Pediatric Subjects 1 Month To 16 Years Of Age With Partial Onset Seizures And Pediatric And Adult Subjects 5 To 65 Years Of Age With Primary Generalized Tonic-Clonic Seizures NCT01463306·Phase 3·Completed·Pfizer's Upjohn has merged with Mylan to form Viatris Inc.·Started 2012
• Trial Comparing the Efficacy and Safety of Lacosamide (LCM) to Carbamazepine Controlled-Release (CBZ-CR); Initial Monotherapy in Epilepsy; Subjects Aged 16 and Older NCT01243177·Phase 3·Completed·UCB BIOSCIENCES GmbH·Started 2011
• Long-Term Safety Study of Retigabine Immediate Release (IR) as Adjunctive Therapy in the Treatment of Adults With Partial-Onset Seizures (POS) NCT01336621·Phase 3·Completed·GlaxoSmithKline·Started 2011
• Once-A-Day Pregabalin For Partial Seizures NCT01262677·Phase 3·Completed·Pfizer's Upjohn has merged with Mylan to form Viatris Inc.·Started 2011
• Study of Retigabine Immediate Release as Adjunctive Therapy to Specified Monotherapy Antiepileptic Treatments in Adults With Partial-Onset Seizures NCT01227902·Phase 3·Completed·GlaxoSmithKline·Started 2010
• Evaluation of the Efficacy and Safety of E2007 (Perampanel) Given as Adjunctive Therapy in Subjects With Refractory Partial Seizures NCT00735397·Phase 3·Completed·Eisai Inc.·Started 2008
• Study Of The Safety And Efficacy Of Lyrica In The Treatment Of Newly Diagnosed Partial Epilepsy NCT00280059·Phase 3·Completed·Pfizer's Upjohn has merged with Mylan to form Viatris Inc.·Started 2006
• Topiramate as Adjunctive Therapy in Infants 1-24 Months for the Control of Partial Onset Seizures NCT00113815·Phase 3·Completed·Johnson & Johnson Pharmaceutical Research & Development, L.L.C.·Started 2005